Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed BAYER CORPORATION (consolidated report)	Individual			
2. Address Address 701 Pennsylvania Ave., NW Suite 720	Address2			
City <u>WASHINGTON</u> State	<u>DC</u> Zip Code <u>20004</u>	Country <u>USA</u>		
3. Principal place of business (if different than line 2)				
City State	Zip Code	Country		
4a. Contact Name b. Telephone N Mr. JONATHAN COLLUM 2027378900	umber c. E-mail jonathan.collum@bayer.com	5. Senate ID# 5632-12		
7. Client Name Self Check if client is a state BAYER CORPORATION (consolidated report)	or local government or instrumentality	6. House ID# 312570000		
TYPE OF REPORT 8. Year 2013 Q1 (1/1 - 3/31) 9. Check if this filing amends a previously filed version of this report Termination 10. Check if this is a Termination Report Termination	Date 11. No Lobbying	g Issue Activity		
INCOME OR EXPENSES - YOU	<u>-</u>			
12. Lobbying INCOME relating to lobbying activities for this reporting period was:	13. Organizations EXPENSE relating to lobbying activities for the second			
<u>Less than \$5,000</u>	<u>Less than \$5,000</u>			
\$5,000 or more \$	\$5,000 or more	<u> </u>		
Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.				
	✓ Method A. Reporting amounts using LDA	A definitions only		
	Method B. Reporting amounts under section Internal Revenue Code	ion 6033(b)(8) of the		
	Method C. Reporting amounts under section Revenue Code	ion 162(e) of the Internal		
Signature Digitally Signed By: Bob Walker Head of Public Policy		Date 07/22/2013		

- 15. General issue area code AGR
- 16. Specific lobbying issues

G 054 A 1 1 B C	E 1 111 4 . C2012			
	, Food, and Jobs Act of 2013 nal Pollutant Elimination System	n (NPDES) permits, End	angered Species, Winter Wheat Cereals Project and I	Pollinators.
U	ture Reform and Risk Managem nal Pollutant Elimination Syster		angered Species, Biotechnology, Winter Wheat Cere	als Project
S. 809 Genetically Enginee	ered Food Right-to-Know Act P	rovisions related to label	ing.	
Discussions on EPA regula	tory actions involving pollinato	r protection and bee heal	th.	
17. House(s) of Congress a	8	heck if None		
U.S. HOUSE OF REPRES	ENTATIVES, U.S. SENATE			
18. Name of each individua	al who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Jean	Reimers			
Matthew	Perin			
Donna	Stephens			
19. Interest of each foreign	entity in the specific issues liste	ed on line 16 above	Check if None	

- 15. General issue area code PHA
- 16. Specific lobbying issues

Meth Lab Elimination	Act of 2005, sections pertaining to Act of 2010, a draft by Sen. Wyden se parts relating to drug supply sect Act	, all parts relating to pseud			
17. House(s) of Congre		Check if None			
U.S. HOUSE OF REPR	RESENTATIVES, U.S. SENATE				
18. Name of each indivi	dual who acted as a lobbyist in this	s issue area			
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New	
Thomas	Lilburn				
Julie Corcoran					
19. Interest of each fore	ign entity in the specific issues list	ed on line 16 above	Check if None		

- 15. General issue area code TAR
- 16. Specific lobbying issues

Discussions related to passage of an omnibus MTB. U.S. Job Creation and Manufacturing Competitiveness Act of 2013 H.R. 6727 (112th Congress) sections related to MTB duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent duty on Desmodur BL 1100/1 duty on Bayhydur BL 5335 duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane , 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin). duty on D-Mannose.
duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent duty on Desmodur BL 1100/1 duty on Bayhydur BL 5335 duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane ,2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on O-Acetylsalicylic acid (Aspirin).
duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent duty on Desmodur BL 1100/1 duty on Bayhydur BL 5335 duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent duty on Desmodur BL 1100/1 duty on Bayhydur BL 5335 duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on O-Acetylsalicylic acid (Aspirin).
duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent duty on Desmodur BL 1100/1 duty on Bayhydur BL 5335 duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane , 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on Desmodur BL 1100/1 duty on Bayhydur BL 5335 duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on Bayhydur BL 5335 duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on O-Acetylsalicylic acid (Aspirin).
duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on O-Acetylsalicylic acid (Aspirin).
duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin).
duty on o-Acetylsalicylic acid (Aspirin).
duty on D-Mannose.
duty on propoxur (2-(1-methylethoxy)phenol methylcarbamate).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name Last Name Suffix Covered Official Position (if applicable) New
Jean Reimers
Matthew Perin
Dakotah Smith
Julie Van Egmond
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

- 15. General issue area code HCR
- 16. Specific lobbying issues

		the effectiveness of medica	ally important antibiotics used in the treatment of h	numan and
	General provisions in the bill			
	Orug User Fee Amendments of 20			
	Generic Drug User Fee Amendme			
	d Animal Generic Drug User Fee l			
	ompounding Quality and Accoun-		sions of the bill. HCR	
•	Congress), as it regards to implement	nentation		
Medical device tax, as it	regards to implementation			
17. House(s) of Congress	s and Federal agencies	Check if None		
U.S. HOUSE OF REPRI	ESENTATIVES, U.S. SENATE			
18. Name of each individ	lual who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Donna	Stephens			
		-		
19. Interest of each foreign	gn entity in the specific issues listo	ed on line 16 above	Check if None	
To a linear out of the linear land,	on entiry in the specific issues its	50 on mic 10 acc (5		
L				

LD-2 Disclosure Form

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code EDU 16. Specific lobbying issues S 553 and HR 1125 Veterinary Loan Repayment Program In support for legislation. 17. House(s) of Congress and Federal agencies Check if None U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE 18. Name of each individual who acted as a lobbyist in this issue area First Name Last Name Suffix Covered Official Position (if applicable) Donna Stephens 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

10/01/2019

15. General issue area code BUD

16. Specific lobbying is	ssues			
FY2014 Appropriation	curity Appropriations Bill. Support s FDA and HHS ted and Further Continuing Approp		and Agriculture Facility funding.	
17. House(s) of Congre	ess and Federal agencies	Check if None		
U.S. HOUSE OF REPI	RESENTATIVES, U.S. SENATE			
18. Name of each indiv	idual who acted as a lobbyist in thi	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Donna	Stephens			
Robert	Thomas			
19. Interest of each fore	eign entity in the specific issues list	ed on line 16 above	Check if None	

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

purposes.	the Toxic Substances Control Act		chemicals are adequately understood and managed,	
	_	Check if None	Tokie Substances Condor riet, and for other purpos	
U.S. SENATE				
18. Name of each indiv	idual who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Julie	Van Egmond			
Dakotah	Smith			
19. Interest of each fore	eign entity in the specific issues liste	ed on line 16 above	Check if None	

of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code ENG 16. Specific lobbying issues S.761 Latest Title: A bill to promote energy savings in residential and commercial buildings and industry, and for other purposes. 17. House(s) of Congress and Federal agencies Check if None U.S. SENATE 18. Name of each individual who acted as a lobbyist in this issue area First Name Last Name Suffix Covered Official Position (if applicable) Julie Van Egmond Dakotah Smith 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf

19. Interest of each foreign entity in the specific issues listed on line 16 above

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code TAX 16. Specific lobbying issues Renewal of tax credits: 25C, 179D, 45L (all 3 energy efficiency related), Corporate R&D tax credit. Credits renewed in 2012 through end of 2013, but now looking for extension beyond Dec 31, 2013. Check if None 17. House(s) of Congress and Federal agencies U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES 18. Name of each individual who acted as a lobbyist in this issue area Covered Official Position (if applicable) First Name Last Name Suffix Julie Van Egmond Dakotah Smith

Check if None

19. Interest of each foreign entity in the specific issues listed on line 16 above

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code MMM 16. Specific lobbying issues Medicare Sustainable Growth Rate Doc fix Provisions related to CMS draft guidance on Service 17. House(s) of Congress and Federal agencies Check if None U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE 18. Name of each individual who acted as a lobbyist in this issue area First Name Last Name Suffix Covered Official Position (if applicable) Robert Thomas

Check if None

of the client during the	e reporting period. Using a separat	e page for each code,	provide information	on as requested. Add additional pag	ge(s) as needed.
15. General issue area	code NAT				
16. Specific lobbying	issues				
HR 527, the Responsi	ble Helium Administration and Sto	ewardship Act			
17. House(s) of Congr	ress and Federal agencies	Check if None			
U.S. HOUSE OF REF	PRESENTATIVES,				
18. Name of each indi	vidual who acted as a lobbyist in t	his issue area			
First Name	Last Name	Suffix	Cover	ed Official Position (if applicable)	New
Robert	Thomas				
19. Interest of each for	reign entity in the specific issues li	sted on line 16 above	Check if	None	
	edata Daga - Campleta O			rmation has shanged	
_	odate Page - Complete O	NLI where reg	istration into	rmation has changed.	
20. Client new address	S				
			24-4-	7:- C- 1-	Countries
			State	Zip Code	Country
	oal place of business (if different th				
City			State	Zip Code	Country
22. New General desc	ription of client's business or activ	rities			
I ODDVICT IID	DATE				
LOBBYIST UP	DAIL				
23. Name of each prev	viously reported individual who is	no longer expected to	act as a lobbyist for	or the client	
First Name	Last Name	Suffix	First Name	Last Name	Suffix
1		5			
2		6			
3					
4		8			
ISSUE UPDAT	E				
24. General lobbying	issue that no longer pertains				

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Street Address City	Address State/Province	Zip	Country		Principal Place of Business (city and state or country)
					City State	Country
26. Name of each previously reported organization that is no longer affiliated with the registrant or client						
1 2	3 4			5		

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address Street Address City State/Province	Country		lace of business tate or country)	Amount of contribution for lobbying activities	Ownership percentage in client
			City State	Country		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1	5	9
2	6	10
3	7	10 11
4	8	12